AHA Again Urges HHS to Protect 340B Program From Drug Companies’ Actions

September 8, 2020

AHA to HHS again expressing concern with recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to our hospital members. While we understand that the Health Resources and Services Administration (HRSA) is further investigating these actions, we urge swift and decisive action to halt these pernicious tactics so as to prevent other manufacturers from following suit.

Related Resources

Letter/Comment
Public
This letter to CMS reiterates AHA’s position that the agency’s Most Favored Nation Proposed Rule should be withdrawn.
Letter/Comment
Public
AHA, others express support of the 340B federal drug pricing program and strongly encourage Congress to protect the program as they consider broader changes to…
Guides/Reports
Tax-exempt hospitals are required to publicly report on the ways in which they improve the health of the communities they serve yearly through the IRS Form 990…
Fact Sheets
Public
The COVID-19 pandemic has altered hospitals’ payer mix, which for some hospitals has temporarily lowered their disproportionate share hospital (DSH) percentage…
Fact Sheets
It is imperative that Congress invest in America’s hospitals and health systems to ensure that the nation’s health care needs can be met today and into the…
Letter/Comment
The American Hospital Association (AHA) would like to share hospital and health system priorities that would benefit patients and communities around the…